Global Sexual Dysfunction Drugs Market 2017-2021
About Sexual Dysfunction Drugs
Sexual dysfunctions include sexual disorders of men and women that can interfere with their sexual performance, leading to unsatisfied sexual intercourse. The major drugs used in this market are PDE5 inhibitors, whereas other drugs such as hormone-related and transurethral also have a presence in the market. Erectile dysfunction (ED) is a highly prevalent sexual dysfunction seen in men. Globally, there has been an increase in the number of ED cases caused due to high blood pressure, obesity, neurological and nerve disorders, prostate cancer, and diabetes among others.
Technavio’s analysts forecast the global sexual dysfunction drugs market to grow at a CAGR of 2.79% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global sexual dysfunction drugs market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Sexual Dysfunction Drugs Market 2017-2021
Technavio recognizes the following companies as the key players in the global sexual dysfunction drugs market: AbbVie, Bayer, Eli Lilly, and Pfizer.
Other Prominent Vendors in the market are: Apricus Biosciences, Emotional Brain, GlaxoSmithKline, Ivix LLX, Leadiant Biosciences, Merck, NexMed, Palatin Technologies and PRA Health Sciences, S1 Biopharma, Takeda, Teva Pharmaceutical Industries, Trimel Biopharma SRL, and Vietstar Biomedical Research.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is Increased focus on generic drugs. The global sexual dysfunction drugs market is currently witnessing an increasing focus of vendors toward the launch of generic drugs in the market. The patent expiration of many ED drugs has led to the entry of generics in the market. The cost-effective nature and the abundant availability of these drugs have led to the increase in the adoption rate of these drugs among physicians and end-users, thus adding to the market revenue.”
According to the report, one of the major drivers for this market is Rising prevalence of sexual dysfunctions. The global sexual dysfunction drugs market is currently witnessing an increasing prevalence rate of sexual dysfunction disorders in men and women. As per the NIH, the incidence rate of ED is 25-30 cases per thousand people per year globally, and this rate is directly proportional to age. A similar pattern is observed with women's sexual dysfunctions.
Further, the report states that one of the major factors hindering the growth of this market is Technological advancements, a threat to drug therapy. Many vendors in the market are innovating in terms of product technology to make ED solutions such as penile implants more reliable and natural-looking. For instance, Titan from Coloplast is made from Bioflex and silicone and is designed to imitate the appearance and mechanism of a natural erection. This will prompt more individuals to undergo penile implant surgeries to treat ED as these solutions provide a near-natural feel of penial erection.
AbbVie, Bayer, Eli Lilly, Pfizer, Apricus Biosciences, Emotional Brain, GlaxoSmithKline, Ivix LLX, Leadiant Biosciences, Merck, NexMed, Palatin Technologies and PRA Health Sciences, S1 Biopharma, Takeda, Teva Pharmaceutical Industries, Trimel Biopharma SRL, Vietstar Biomedical Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook